Study of Thymitaq™ for Cancer Treatment
Author Information
Author(s): Jodrell D I, Bowman A, Rye R, Byrne B, Boddy A, Rafi I, Taylor G A, Johnston A, Clendeninn N J
Primary Institution: ICRF Medical Oncology Unit, Western General Hospital
Hypothesis
Can the oral administration of Thymitaq™ (nolatrexed dihydrochloride) be safely escalated in patients?
Conclusion
The study found that while Thymitaq™ showed antiproliferative effects, nausea and vomiting were significant side effects at higher doses.
Supporting Evidence
- Nolatrexed was administered orally at escalating doses over a 10-day period.
- Common toxicities included nausea, vomiting, and liver function test abnormalities.
- Three out of nine patients at 429 mg/m²/day experienced grade 3 nausea.
- 17 out of 22 treatment courses were completed with prophylactic antiemetics.
Takeaway
Doctors tested a new cancer drug called Thymitaq™ to see how much they could give patients without making them too sick, and they found that it worked but made some people feel nauseous.
Methodology
Patients received oral Thymitaq™ every 6 hours for 10 days, with doses escalated from 80 to 572 mg/m²/day.
Limitations
The study was limited by the occurrence of dose-limiting toxicities such as nausea and vomiting.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website